Mike Ryan

Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products designed to harness the patient’s immune system to combat and eradicate cancer. Its lead immuno-oncology drug candidate, sotigalimab, is a potent immune-activating antibody against CD40 currently in Phase 2 clinical development.

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has developed two proprietary product candidates: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Compugen also has a clinical stage partnered program, rilvegostomig (previously AZD2936), a PD-1/TIGIT bi-specific derived from COM902, in Phase 2 development by AstraZeneca through a license agreement for the development of bi-specific and multi-specific antibodies. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The most advanced program, COM503 is in IND enabling studies. COM503 is a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding protein and IL-18, thereby freeing natural IL-18 to inhibit cancer growth in the tumor microenvironment. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Calithera Biosciences is a clinical-stage biopharmaceutical company pioneering the discovery and development of targeted therapies that disrupt cellular metabolic pathways to preferentially starve tumor cells and enhance immune-cell activity. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients.

NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare, skincare, and wound care products. NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution channels such as Amazon. DERMAdoctor® offers more than 30 OTC dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by Pioneer Pharma (Hong Kong) Company Ltd. NovaBay Pharmaceuticals, Inc. is publicly traded (NYSE: NBY).

BrokersWeb.com is a premium, vertically-targeted, pay-per-click (PPC) traffic source for over 150 top-rated insurance advertisers. With roots as an insurance sales organization, we understand the conversion needs of our clients. BrokersWeb has grown into one of the leading ROI-driven, online marketing channels for PPC advertisers, delivering tens of thousands of ultra-targeted consumers to our advertising clients on a daily basis. The BrokersWeb Affiliate Program offers publishers the highest monetization solution for those who can deliver high-quality queries for insurance products such as Auto Insurance, Health Insurance, Life Insurance, Home Insurance and Medicare Supplement. The program represents an opportunity for these publishers to increase their revenues by implementing a BrokersWeb PPC advertising feed integrated seamlessly into their websites.

drugstore.com, inc. (NASDAQ: DSCM) is a leading online provider of health, beauty, vision, and pharmacy products. Our portfolio of brands includes: drugstore.com™, Beauty.com™, and VisionDirect.com™. All are accessible from http://www.drugstore.com and provide a convenient, private, and informative shopping experience while offering a wide assortment of more than 45,000 products at competitive prices. The drugstore.com pharmacy is certified by the National Association of Boards of Pharmacy (NABP) as a Verified Internet Pharmacy Practice Site (VIPPS) and operates in compliance with federal and state laws and regulations in the United States.

Not sure what to write? Check out your company's website.Proteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target certain cancers and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. In addition to its lead product candidate, carfilzomib (PR-171), which is delivered intravenously and is currently in multiple clinical trials to evaluate its safety and efficacy in multiple types of cancer, Proteolix is developing next generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic potential of this new target class. Proteolix is headquartered in South San Francisco.

Silverbear Capital is globally positioned consulting and investment banking firm, utilizing a team of seasoned professionals primarily experienced in securities collateralized lending, and international banking and finance. We are global in scope and reach, with extraordinary access in Southeast Asia and mainland China.

Imagine there was a link to securely credential anything, anywhere, anonymously… We simplify how individuals securely prove and share their identity online and provide fast, secured access to verified personal data. Digital identities are becoming the future standard practice across most industries. While using traditional identification methods, individuals are often required to provide more data than necessary. How We Help: Our platform enables organisations to issue a single, reusable, decentralised, digital credential that validates an individuals identity without openly revealing sensitive information. It can integrate data owned by third parties so that digital credentials can serve as an ecosystem, binding a persons identity to their information that is securely stored on the users device in a secure mobile wallet. Our Four Components: Q-Link – a connected data platform for managing, verifying, and issuing digital documents, medical tests and data between approved stakeholders. Q-Wallet – a digital wallet that uses AES-256 encryption that enables people to store and share personal details, including health tests, government IDs, work passes, tickets and more via QR codes. Q-Authenticator – A powerful application that enables organisations to determine entry conditions, verify credentials for employees/customers, and acts as an access control through contactless scanning and verification of identity. Q-Intelligence – Provides integration options based on RESTful APIs to interface with external systems, including off-the-shelf and custom-built modules for any client-driven requirement.

Consummate Technologies delivers decisive business and technology leadership with vision. We recognize the need for rapidly changing business and technology environments and provide cloud-based migration and digital transformation services across multiple platforms. We are the forefront leader in B2BB2C outsourced Sales/Services/Commerce Clouds/AWS and Digital Transformations across North America and are powered by Salesforce Cloud Einstein Analytics, and Microsoft Azure. Our DevOps, AI & IoT for CPG, Retail, & Food expertise has completed over 1,000 Salesforce Implementations, successfully serving clients like Xerox, Mars, Heineken, and Expedia. One of the things that sets us apart is our unique multiple core expertise across Salesforce, Microsoft Azure & AWS. This coupled with our customer success first, long-term approach is the key driver of our 140% customer retention across 10+ years. Our Annual Release Update Services (ARUS) has saved our clients $1B+ in IT costs over the years. Follow us to gain insights based on the experience of over 1,000 implementations with clients like Xerox, Mars, Heineken, and Expedia, we have developed some of the best use cases in the industry. Technology Focus: • Cloud CRM: Salesforce, MS Dynamics, Azure, AWS, SAP C4C, Oracle CRM and Zoho CRM • Cloud ERP: SAP ERPs, Oracle ERPs, Microsoft ERPs and Ramco ERP • Digital Technologies: Cloud Computing, IoT, DevOps, AI & ML, Data Analytics,

We are an interdisciplinary team of passionate Physician Innovators, Surgeons, Data Scientists, Engineers, Computational Biologists, Geneticists, Public Health Executives, and Lawyers. Collectively, we are innovators, fascinated by science in all its manifestations. We feel, morbidities and mortalities don’t occur in isolation… they offer signals long before symptoms become evident, either clinical and/or social. Core to our mission is the belief that digitally enabled health services powered by deep science applications can help close care gaps. We believe understanding propensity for clinical and social risk early is key to improving outcomes, enhancing value, and promoting equity. Our voyage began with a vision to eradicate maternal and infant mortality and morbidity by putting AI behind medicine, biology, and social determinants of health. We use advanced computational sciences, namely AI and deep learning to analyze massive volumes of data (of all kinds – medical records, notes, conversations, images, genetics, claims, surveys, drug research, drug usage etc.) to derive insights that can empower payers, providers, drug makers and public health professionals. Want to experience how our AI and Machine learning driven risk quantification platform can help you? If so, contact us at info@cognitivecare.com Notable Milestones: AWS Healthcare Accelerator 2022 Cohort Mass Challenge/MITRE Maternal Health Equity Challenge Semifinalist Bill & Melinda Gates Foundation AI/Maternal Health Risk Stratification Grantee L V Prasad Eye Institute Partnership ACESO partnership